Laura Luisa Kilarski (Laura L Kilarski)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Randomized Controlled Trial

Attention Deficit Hyperactivity Disorder

Clinical Practice

Top Venues

Journal of clinical medicine

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Nikolas Gaspar, Laura Luisa Kilarski, Helena Rosen, Maximilian Huppertz, Alexandra Philipsen, Henrik Rohner
Attention Deficit Hyperactivity Disorder: A Risk Factor for Premature Discontinuation of Inpatient Opioid Withdrawal Treatment. Journal of clinical medicine 13 (11) (2024)
Nikolas Gaspar, Laura Luisa Kilarski, Helena Rosen, Maximilian Huppertz, Alexandra Philipsen, Henrik Rohner
Attention Deficit Hyperactivity Disorder: A Risk Factor for Premature Discontinuation of Inpatient Opioid Withdrawal Treatment. Journal of clinical medicine 13 (11) (2024)
Teuntje A D Pelgrim, Alexandra Philipsen, Allan H Young, Mário Francisco Juruena, Esther Jiménez, Eduard Vieta, Marin Jukić, Erik Van der Eycken, Urs Heilbronner, Ramona Moldovan, Martien J H Kas, Raj R Jagesar, Markus M Nöthen, Per Hoffmann, Noam Shomron, Laura Luisa Kilarski, Thérèse van Amelsvoort, Bea C M Campforts, null The Psy-PGx Consortium, Roos van Westrhenen
A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Teuntje A D Pelgrim, Alexandra Philipsen, Allan H Young, Mário Francisco Juruena, Esther Jiménez, Eduard Vieta, Marin Jukić, Erik Van der Eycken, Urs Heilbronner, Ramona Moldovan, Martien J H Kas, Raj R Jagesar, Markus M Nöthen, Per Hoffmann, Noam Shomron, Laura Luisa Kilarski, Thérèse van Amelsvoort, Bea C M Campforts, null The Psy-PGx Consortium, Roos van Westrhenen
A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)